Paradigm Biopharmaceuticals Ltd
ASX:PAR
Paradigm Biopharmaceuticals Ltd
ASX:PAR
Price:
0.275 AUD
-3.51%
Market Closed
Updated:
May 2, 2024
Section:
Relative Value
The Relative Value of one
PAR
stock under the Base Case scenario is
1.602
AUD.
Compared to the current market price of 0.275 AUD,
Paradigm Biopharmaceuticals Ltd
is
Undervalued by 83%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
PAR
Relative Value
Base Case
1.602
AUD
Undervaluation 83%
Valuation Multiples
Multiples Across Competitors
PAR Competitors Multiples
Paradigm Biopharmaceuticals Ltd Competitors
Paradigm Biopharmaceuticals Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| AU |
|
Paradigm Biopharmaceuticals Ltd
ASX:PAR
|
96.7m AUD | 11.2 | -1.4 | -0.9 | -0.9 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
281.3B USD | 5.2 | 58.4 | 12.7 | 19.4 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
148.1B USD | 5.3 | 22 | 16.4 | 24.5 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
103.8B USD | 10.5 | 28.7 | 23 | 24 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
101.7B USD | 7.8 | 25.7 | 17.2 | 18.9 | |
| AU |
|
CSL Ltd
ASX:CSL
|
133B AUD | 6.1 | 35.1 | 21.3 | 26.4 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
81.1B USD | 3 | 167.6 | 6.7 | 8.8 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
45.8B USD | 6.7 | -9.7 | -10.4 | -8.9 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
31.3B USD | 3.2 | 26.8 | 13.8 | 17.2 | |
| KR |
|
Celltrion Inc
KRX:068270
|
38.9T KRW | 17.9 | 72.5 | 44.4 | 61.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
